Duloxetine in major depressed patients resistant to SSRIS and/or venlafaxine

Psychiatria Danubina

Volumn 22, Issue SUPPL. 1, 2010, Pages

  Pitchot, William ^a   Scantamburlo, Gaby ^a   Ansseau, Marc ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Duloxetine; Major depression; Remission; SNRI; SSRI

Indexed keywords

DULOXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; NAUSEA; REMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; HUMANS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 78649915325     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Brecht S et al.: Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. J Clin Psychiatry 2010 (Epub ahead of print).
2. Detke MJ et al.: Duloxetine in the acute and long term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004; 14: 457-470. (Pubitemid 39626894)
3. Goldstein DJ et al: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacology 2004; 24:389-399. (Pubitemid 38944137)
4. Papakostas GI et al.: Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62: 1217-1227.
5. Papakostas GI et al.: Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008; 63: 699-704.
6. Raskin J et al.: Duloxetine in the long term treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 1237-1244.
7. Rush AJ, Trivedi MH, Wisniewski SR, et al. - Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231-1242
8. Those ME et al.: Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007; 27: 672-676.
9. Wernicke JF et al.: An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007; 8:503-513.